Cabaletta Bio Inc.

1.22
0.05 (4.27%)
At close: Apr 02, 2025, 3:59 PM
1.23
1.23%
After-hours: Apr 02, 2025, 07:57 PM EDT
4.27%
Bid 1.2
Market Cap 59.39M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -2.34
PE Ratio (ttm) -0.52
Forward PE -0.93
Analyst Buy
Ask 1.26
Volume 1,225,389
Avg. Volume (20D) 1,203,871
Open 1.18
Previous Close 1.17
Day's Range 1.16 - 1.27
52-Week Range 1.16 - 19.04
Beta 2.58

About CABA

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART,...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 25, 2019
Employees 154
Stock Exchange NASDAQ
Ticker Symbol CABA
Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for CABA stock is "Buy." The 12-month stock price forecast is $23, which is an increase of 1793.00% from the latest price.

Stock Forecasts
4 months ago
-19.84%
Cabaletta Bio shares are trading lower after Wells... Unlock content with Pro Subscription
7 months ago
-34.37%
Cabaletta Bio shares are trading lower. The company reported Q2 financial results.